é«å®ç ãšæœ°çæ§å€§è žçã®ç æ 圢ææ©æ§ã®è§£æãž
ïŒæœ°çæ§å€§è žçç¹ç°çèªå·±æäœãšã®é¢é£è§£æïŒ
æŠèŠ
ãçååŠç 究æïŒçç ïŒçåœå»ç§åŠç 究ã»ã³ã¿ãŒã²ãã 解æå¿çšç 究ããŒã ã®å¯ºå°Ÿç¥å¯å²ããŒã ãªãŒããŒïŒé岡çç«ç·åç é¢èšåºç 究éšå ç«ç 究éšé·ãé岡çç«å€§åŠè¬åŠéšã²ãã ç æ 解æè¬åº§ç¹ä»»ææïŒãç³å·åªæš¹ç 究å¡ãã®å ±åç 究ã°ã«ãŒãã¯ã朰çæ§å€§è žçïŒUCïŒ[1]ã®ç¹ç°çèªå·±æäœ[1]ã§ããæã€ã³ãã°ãªã³Â αvβ6 æäœ[1]ããé«å®ç ïŒTAKïŒ[1]æ£è ã«ãããŠããããã«èªããããããšãããæ¬æäœã«ããå ±éã®ç æ 圢ææ©æ§ãžã®é¢äžãçãããŸããããäºæ³ã«åããŠé«å®ç ã®éºäŒçãªã¹ã¯ãå䜵çãšæ¬æäœã®ååšã«ææãªé¢é£ããªãããšãçºèŠããŸããã
æ¬ç 究ææã¯ãå ±éã®éºäŒçèæ¯ãèŠããé«å®ç ãšæœ°çæ§å€§è žçã«ãããç æ 圢ææ©æ§ã®å ±éç¹ããã³çžéç¹ã®è§£æã«åºã¥ããäž¡çŸæ£ã®èšºæãæ²»çãäºåŸäºæž¬ãªã©ãžã®å¿çšã«è²¢ç®ãããšæåŸ ã§ããŸãã
ä»åãå ±åç 究ã°ã«ãŒãã¯ãé«å®ç æ£è  227 人ã«ãããŠãæã€ã³ãã°ãªã³ αvβ6æäœã®æç¡ãšæœ°çæ§å€§è žçå䜵ã®æç¡ããã³Â HLA éºäŒå[2]ãšã®é¢é£ãæ€èšããŸãããæã€ã³ãã°ãªã³Â αvβ6 æäœãã朰çæ§å€§è žçå䜵ã®ãªãé«å®ç æ£è ã«ãããŠããããã«èªãããããã®ã®ãäž¡çŸæ£ã®å ±éãªã¹ã¯é¢é£Â HLA éºäŒå HLAB*52[2]ã®åœ±é¿ã¯ææã«èªãããããèŽæ»çãªå䜵çã§ãã倧åèåŒééäžå šçãšé¢é£ããªãããšãèŠãã ããŸããã
é«å®ç ãšæœ°çæ§å€§è žçãæã€ã³ãã°ãªã³ αvβ6 æäœãšã®é¢é£
èæ¯
ãé«å®ç ïŒTAKïŒã¯ã倧åèã«ççãèµ·ããèªå·±å ç«æ§è¡ç®¡çã®äžã€ã§ããã20ïœ30 æ³ä»£ã®è¥ã女æ§ãå€ãçºçããŸããäžæ¹ã朰çæ§å€§è žçïŒUCïŒãçºç幎霢ã¯é«å®ç ãšåæ§ã§ãããé«å®ç ã®ãããªæ確ãªç·å¥³å·®ã¯èªããããŸããã
é«å®ç æ£è ã§ã¯æœ°çæ§å€§è žçã®å䜵ãéé«å®ç æ£è ãããã¯å¥åžžè ãããé«ãããšãç¥ãããŠããã朰çæ§å€§è žçå䜵é«å®ç æ£è ã«ãããŠã¯éå䜵æ£è ãããé«å®ç ã®çºç幎霢ãè¥ããHLA-B*52 ä¿å è ãææã«å€ãããšãç¥ãããŠããŸãã泚ïŒãHLA-B*52 ã¯æœ°çæ§å€§è žçã®ãªã¹ã¯éºäŒåã§ãããããšãããäž¡çŸæ£ã«ã¯å ±éã®éºäŒèæ¯ã«åºã¥ããç æ 圢ææ©æ§ãååšãããšèããããŠããŸãããäžæ¹ãé«å®ç ã朰çæ§å€§è žçãšãã«è¡ç®¡å ç®çŽ°èã«å¯Ÿããèªå·±æäœãäžå¿ã«ããŸããŸãªèªå·±æäœããããŸã§å ±åãããŠããŸãããäžã§ãã朰çæ§å€§è žçã«ç¹ç°çãªæäœã§ããæã€ã³ãã°ãªã³Â αvβ6 æäœãåå®ãããæ床[3]ãšç¹ç°åºŠ[3]ã®é«ãããèšåºã«ãããæçšæ§ãæ¬ç 究ã®å ±åç 究è ãã«ãã£ãŠæè¿å ±åãããŸããããã ãé«å®ç æ£è ã«ãããæã€ã³ãã°ãªã³Â αvβ6 æäœã®æ€èšã¯ãããŸã§å ±åããããŸããã§ããããã ãé«å®ç ãšæœ°çæ§å€§è žçã®éã«å ±éã®éºäŒèæ¯ãååšããããšããããæã€ã³ãã°ãªã³Â αvβ6 æäœãšé«å®ç ã®é¢é£ãæ€èšããããšã¯äž¡çŸæ£ã®ç æ 解æã«ãããŠæçšã§ãããšèããŸããã
Â
泚ïŒTerao, C., et al. Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap, ArthritisRheumatol, 2015. DOI: 10.1002/art.39157
ç 究ææ³ãšææ
ãå ±åç 究ã°ã«ãŒãã¯ã京éœå€§åŠç é¢ãé·åŽå€§åŠç é¢ãæ±å倧åŠç é¢ã«éé¢ããé«å®ç æ£è ããæäŸãããè¡æ¶²ãµã³ãã«ã®ãã¡ãDNA ã®éºäŒååã¿ã€ãã³ã°[4]ãšæã€ã³ãã°ãªã³Â αvβ6 æäœäŸ¡ã®æž¬å®æŽã®ãã 227 人ã察象ãšããŠãè¡æŒ¿ïŒãã£ãããïŒäžã®æã€ã³ãã°ãªã³Â αvβ6 æäœãšæœ°çæ§å€§è žçå䜵ã®æç¡ããªã¹ã¯Â HLAéºäŒåã§ãã HLA-B*52 ã®æç¡ãšã®é¢é£ã調ã¹ãŸããã
æã€ã³ãã°ãªã³Â αvβ6 æäœéœæ§çã«ã€ããŠãé«å®ç æ£è å šäœã§ã¯Â 7.05ïŒ ïŒ16/227ïŒã朰çæ§å€§è žçå䜵ã®ãªãé«å®ç æ£è ã§ããã 3.18ïŒ ïŒ4/152ïŒã§ãã£ãã®ã«å¯ŸããŠã朰çæ§å€§è žçå䜵ã®ããé«å®ç æ£è ã§ã®éœæ§çã¯Â 87.5ïŒ ïŒ7/8ïŒãšææã«é«ãïŒãªããºæ¯Â 121ãp å€Â 2.99Ã10-10ïŒãæã€ã³ãã°ãªã³Â αvβ6 æäœã®æœ°çæ§å€§è žçç¹ç°æ§ãæ¹ããŠç¢ºèªãããŸããïŒå³Â 1ïŒãäžæ¹ã§ãããããªããã朰çæ§å€§è žçå䜵ã®ãªãé«å®ç æ£è ã«ãããŠãæã€ã³ãã°ãªã³Â αvβ6 æäœãéœæ§ã§ãã£ãããšã¯æ³šç®ã«å€ããããšã§ãããäž¡çŸæ£ã®ãªã¹ã¯éºäŒåã§ãã HLAB*52 ã®æç¡ã«ã€ããŠã¯ãçµ±èšåŠçã«ææãªå·®ã«ã¯è³ããªãã£ããã®ã®ãæäœéœæ§çŸ€ã«ãããŠÂ HLA-B*52 éœæ§çãé«ãåŸåã«ãããŸããïŒãªããºæ¯Â 2.84ãp å€0.068ïŒïŒè¡š 1ïŒã
å³Â 1 èšåºãããã£ã«å¥ã®æã€ã³ãã°ãª
ãã ã³Â αvβ6 æäœéœæ§ç
ã°ã©ãã¯ãå·Šãã controlïŒå¯Ÿç §çŸ€ïŒãTAKïŒé«å®ç æ£è å šäœïŒãTAK_UCïŒæœ°çæ§å€§è žçå䜵é«å®ç æ£è ïŒãTAK_nonUCïŒæœ°çæ§å€§è žçå䜵ã®ãªãé«å®ç æ£è ïŒãTAK_B52+ïŒHLA-B*52 éœæ§é«å®ç æ£è ïŒãTAK_B52-ïŒHLA-B*52 é°æ§é«å®ç æ£è ïŒã®æã€ã³ãã°ãªã³Â αvβ6 æäœéœæ§çã瀺ãã
衚 1 æ¬ç 究ã®æ£è èæ¯
CRP ã¯Â C-reactive proteinïŒäœå ã§ççãèµ·ãããšåæãããã¿ã³ãã¯è³ªã®ææšïŒãITAS2010 ã¯éç床ã¹ã³ã¢ã§ãã Indian Takayasu arteritis Activity Score 2010ãéç床ææ°ã¯ååŽçç 究çã«ããéç床åé¡ïŒâ -⠀床ïŒãå¹³åå€ã¯Â±æšæºåå·®ã§èšèŒãïŒ ïŒå ã®æ°åã¯ãå®éã®äººæ°æ¯ã
ã次ã«ãæã€ã³ãã°ãªã³Â αvβ6 æäœãšæœ°çæ§å€§è žçããã³Â HLA-B*52 ã®é¢é£ã«ã€ããŠããžã¹ãã£ãã¯ååž°åæã¢ãã«[5]ãçšããŠæ€èšããŸãããæã€ã³ãã°ãªã³Î±vβ6 æäœãšæœ°çæ§å€§è žçã¯Â HLA-B*52 ã®æç¡ã«é¢ä¿ãªã匷ãé¢é£ã瀺ãããšã確èªãããŸããïŒãªããºæ¯ 212.8ãp å€Â 3.9410-6ïŒãäžæ¹ãHLA-B*52 ãšæã€ã³ãã°ãªã³Â αvβ6 æäœãšã®éã«ææãªé¢é£ã¯èªããããã衚 1 ã§èªããããåŸåã¯æœ°çæ§å€§è žçå䜵ã®åœ±é¿ã§ãã£ããšèããããŸããããŸãã朰çæ§å€§è žçå䜵ã®ãªãé«å®ç æ£è ã«ãããŠæã€ã³ãã°ãªã³Â αvβ6 æäœãèªããããããšãèžãŸããŠããããã®æ£è ã«ãããæã€ã³ãã°ãªã³Â αvβ6 æäœãšÂ HLA-B*52 ãšã®é¢é£ãããžã¹ãã£ãã¯ååž°åæã«ãŠæ€èšããçµæãçµ±èšåŠçã«ææãªé¢é£ãèªããŸããã§ããããŸããé«å®ç ã®éçå䜵çã§ãã倧åèåŒééäžå šçã«ã€ããŠãæã€ã³ãã°ãªã³Â αvβ6 æäœãšã®é¢é£ã¯èªããããŸããã§ããã
ãããã®çµæãããé«å®ç æ£è ã«ãããæã€ã³ãã°ãªã³Â αvβ6 æäœã®ç£çã¯HLA-B*52 ãé¢é£ããæ©åºãšã¯ç°ãªãããšã瀺åãããŸããã
ä»åŸã®æåŸ
ã朰çæ§å€§è žçå䜵ã®ãªãé«å®ç æ£è ã«ãããŠæã€ã³ãã°ãªã³Â αvβ6 æäœã®ææãªé¢é£ãèªããããªãã£ãããšã¯ãå ±éã®éºäŒçèæ¯ãæããé«å®ç æ£è ã«ãããŠããæ¬æäœã朰çæ§å€§è žçã«å¯ŸããŠç¹ç°æ§ãé«ãããšãæå³ããŠãããäž¡çŸæ£ã«ãããç æ 圢ææ©æ§ã®éãã説æããèŠçŽ ã®äžã€ã§ãããšèããããŸãããŸããå®éã®æ£è ã«ãããæã€ã³ãã°ãªã³Â αvβ6 æäœã®äœçšã®è§£æãªã©ãä»åŸãããªãç 究ã®é²å±ã«ãããäž¡çŸæ£ã®ç æ 解æã«ã€ãªããåŸãèå³æ·±ãç¥èŠã§ãããšèããããŸãã
ããã«å®èšåºã«ãããŠããæ¬æäœãé«å®ç æ£è ã§å䜵ã®å€ã朰çæ§å€§è žççºçã®ã¹ã¯ãªãŒãã³ã°ã«æçšã§ããããšã瀺åãããé«å®ç æ£è ã®ãããžã¡ã³ãã«è²¢ç®ãããšæåŸ ãããŸãã
è£è¶³èª¬æ
[1] 朰çæ§å€§è žçïŒUCïŒãèªå·±æäœãæã€ã³ãã°ãªã³Â αvβ6 æäœãé«å®ç ïŒTAKïŒ
å ç«æ©æ§ã¯çŽ°èããŠã€ã«ã¹ãªã©ã®å€æ¥ã®ç°ç©ïŒæåïŒãæé€ããèªå·±é²è¡æ©æ§ã§ããããéºäŒèŠå ãç°å¢èŠå ãªã©ã«ããèªå·±ãéèªå·±ãšèªèããŠé害ãèµ·ããããšãããïŒèªå·±å ç«ïŒãèªå·±å ç«æ©åºã«ããçŸæ£ãå æ¬ããŠèªå·±å ç«çŸæ£ãšåŒã¶ãé«å®ç ïŒTAKïŒã¯å€§åèãšãã®åæã«å¯Ÿããèªå·±å ç«ã朰çæ§å€§è žçïŒUCïŒã¯å€§è žç²èã«å¯Ÿããèªå·±å ç«ã«ãã£ãŠåŒãèµ·ãããããèªå·±å ç«çŸæ£ã«ãããŠã¯ãæ£è è¡äžã«èªå·±æäœãšåŒã°ããã¿ã³ãã¯è³ªãååšããããšããããçŸæ£ã«ç¹ç°çãªèªå·±æäœã¯èšºæäžæçšã§ãããçŸæ£æŽ»åæ§ãšäžŠè¡ããŠå€ãäžäžããèªå·±æäœã¯ãçŸæ£æŽ»åæ§ã®è©äŸ¡ãæ²»ççµéã®ã¢ãã¿ãŒã«æçšã§ãããæã€ã³ãã°ãªã³Â αvβ6 æäœã¯æœ°çæ§å€§è žçã«ç¹ç°æ§ãé«ãããã®æäœã®ååšã«ããã€ã³ãã°ãªã³Â αvβ6 ãšãã£ãããã¯ãã³çµåãé»å®³ãããããšã§å€§è žäžç®å·å®³ã«è³ããšèããããŠãããæ¬æäœã¯çŸæ£æŽ»åæ§ãšãçžé¢ããŠå€ãå€åããèªå·±æäœã§ãããTAK ã¯Â Takayasu arteritisãUC ã¯Â ulcerative colitis ã®ç¥ã
Â
[2] HLA éºäŒåãHLA-B*52
HLAïŒããçœè¡çæåïŒhuman leukocyte antigen ãããã¯Â major histocompatibilitycomplexïŒã¯çœè¡çããã³å皮现èè¡šé¢ã«çºçŸããååã§ããã®è¡šé¢ã«ã¿ã³ãã¯è³ªãèŒããè€åäœãå ç«çŽ°èã®äžçš®ã§ãã T 现èã®å容äœã«ãã£ãŠèªèãããããšã§ãèªå·±ãšéèªå·±ã®åºå¥ãšåŒãç¶ãã®å ç«å¿çã決å®ããããHLA ã¯å€æ§æ§ã«å¯ãã§ãããå€æ¥æåã«å¯Ÿããå€æ§ãªå ç«å¿çã«ãããŠéèŠã§ããäžæ¹ã§ããã®å€æ§æ§ãçš®ã ã®èªå·±å ç«çŸæ£ãšé¢é£ããããšãåãã£ãŠãããé«å®ç ãšæœ°çæ§å€§è žçã«é¢é£ãã HLAéºäŒåãšããŠÂ HLA-B*52 ãç¥ãããŠããã
Â
[3] æ床ãç¹ç°åºŠ
ããæ€æ»ãè¡ã£ããšãã«ãçŸæ£ã®ãã人ã®äžã§æ€æ»ãéœæ§ã«ãªãå²åãæ床ãçŸæ£ã®ãªã人ã®äžã§æ€æ»ãé°æ§ã«ãªãå²åãç¹ç°åºŠãšåŒã³ãæ€æ»ç²ŸåºŠã®ææšãšãªããæ床ãšç¹ç°åºŠã¯ãã¬ãŒããªãé¢ä¿ã«ããããã®é¢ä¿ãèŠèŠåããæ²ç·ã¯Â receiver operatingcharacteristicïŒROCïŒæ²ç·ãšåŒã°ãã
Â
[4] éºäŒååã¿ã€ãã³ã°
éºäŒååã¯å人ããšã«ç°ãªã DNA äžã®å¡©åºé åã®éãã§ãããããŸããŸãªçã DNAé åãé«å¯åºŠã«æŽååºå®ãããããäžã§ããµã³ãã«Â DNA ãšã®çžè£çãªçµåãä»ããŠãµã³ãã«Â DNA ã®éºäŒååã決å®ããæè¡ãéºäŒååã¿ã€ãã³ã°ãšãããçŸåšã§ã¯åçš®ã®ãã€ã¯ãã¢ã¬ã€ããããããããµã³ãã«ã®äººçš®ãç®çã«å¿ãããããã®çš®é¡ãéžæãããã
Â
[5] ããžã¹ãã£ãã¯ååž°åæã¢ãã«
äžã€ïŒåå€éïŒãããã¯è€æ°ïŒå€å€éïŒã®èª¬æïŒç¬ç«ïŒå€æ°ãçšããŠãç¹å®ã®ç®çïŒåŸå±ïŒå€æ°ãäºæž¬ãã解ææ¹æ³ã®äžã€ã§ãããå»åŠçµ±èšã§ãã³ãã³äœ¿çšããããç®çïŒåŸå±ïŒå€æ°ã¯ããæã€ã³ãã°ãªã³Â αvβ6 æäœéœæ§ã»æã€ã³ãã°ãªã³Â αvβ6 æäœé°æ§ããªã©ã®å矩å€æ°ã§ããã